Drug Information

Drug (ID: DG01802) and It's Reported Resistant Information

• Name: Delphinidin
• Synonyms: Delphinidin chloride; 528-53-0; Delphinidin; Delphinidine; Delphinidol; Delfinidol chloride; Ephdine; 8012-95-1; UNII-EM6MD4AEHE; Delphinidin (chloride); 1-Benzopyrylium, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-, chloride; EM6MD4AEHE; 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol chloride; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)benzopyrylium chloride; IdB 1056; 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol;chloride; CHEBI:38701; 3,3',4',5,5',7-Hexahydroxyflavylium chloride; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyrylium chloride; MFCD00016663; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)chromenylium chloride; Delphinidine; Delphinidol; Ephdine; IdB 1056;Delfinidol chloride; Delphinidin; CHEMBL590878; Delphinidin chloride, analytical standard; 3,3',4',5,5',7-Hexahydroxy-2-phenylbenzopyrylium chloride; CCRIS 2518; EINECS 208-437-0; C15H11O7.Cl; Delphinidinchloride; 2-(3,4,5-trihydroxyphenyl)-1-benzopyrylium-3,5,7-triol; SCHEMBL22369; IdB-1056; DTXSID701019982; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromenium chloride; BCP15819; HY-N2409; 6267AF; AKOS027326494; AC-35150; AS-78369; CS-0022610; FT-0645153; FT-0665679; Q367258; Flavylium 3,3',4',5,5',7-hexahydroxy-, chloride (8CI); UNII-R911H793SU component FFNDMZIBVDSQFI-UHFFFAOYSA-N
• Indication:
  In total 1 Indication(s)
  Cardiovascular disease [ICD-11: BA00-BE2Z]; Phase 2; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Breast cancer [ICD-11: 2C60]; [1]
• Target: Vascular endothelial growth factor receptor 2 (KDR); VGFR2_HUMAN; [1]
• Formula: 1
• IsoSMILES: C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O.[Cl-]
• InChI: InChI=1S/C15H10O7.ClH/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6;/h1-5H,(H5-,16,17,18,19,20,21);1H
• InChIKey: FFNDMZIBVDSQFI-UHFFFAOYSA-N
• PubChem CID: 68245
• ChEBI ID: CHEBI:38701
• TTD Drug ID: D0ZN1R

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Breast cancer [ICD-11: 2C60]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: HOX transcript antisense RNA (HOTAIR) [1]

• Resistant Disease: Breast adenocarcinoma [ICD-11: 2C60.1]
• Molecule Alteration: Up-regulation; Interaction
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: MCF-7 cells; Breast; Homo sapiens (Human); CVCL_0031
• In Vitro Model: MDA-MB-231 cells; Breast; Homo sapiens (Human); CVCL_0062
• In Vitro Model: MDA-MB-453 cells; Breast; Homo sapiens (Human); CVCL_0418
• In Vivo Model: Female Sprague-Dawley rats carcinogenesis model; Rattus norvegicus
• Experiment for Molecule Alteration: Western bloting analysis; RIP experiments assay; ChIP assay
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: Delphinidin suppresses breast carcinogenesis through the HOTAIR/microRNA-34a axis.

References

• Ref 1: Delphinidin suppresses breast carcinogenesis through the HOTAIR/microRNA-34a axisCancer Sci. 2019 Oct;110(10):3089-3097. doi: 10.1111/cas.14133. Epub 2019 Sep 16.